Chile is not a particularly large pharma and healthcare market in Latin America, as it has a comparatively small and healthy population in terms of incidence of communicable diseases. However, the changing epidemiological profile and the rapidly ageing population are allowing the sector to grow at a faster pace than the regional average. The main drug segment in terms of value is that of patented drugs, although generic drugs enjoy the largest growth opportunities. Over 2012-2017, total health expenditure rose at a CAGR of 11.6%, driven by a solid increase of government spending on healthcare. In 2017, Chile allocated 8.1% of its GDP on healthcare, a figure that will continue to grow in the short term. The country continues to rely on imports to meet its domestic demand for drugs. In 2012-2017, trade deficit in pharmaceuticals followed a steady upward trend to reach USD 1.2bn in 2017.

01 EXECUTIVE SUMMARY

02 SECTOR IN FOCUS

03 COMPETITIVE LANDSCAPE

04 COMPANIES IN FOCUS

05 REGULATORY ENVIRONMENT

06 PHARMACEUTICALS

07 HEALTHCARE

08 RETAIL CHANNELS